blue_cubecenterhome

Custom Search

Information About Psychtropic Drugs

What is Strattera?
GENERIC NAME: Atomoxetine
BRAND NAMES: Strattera

gray_line

Abilify
Adderall
Ambien
Anafranil
Asendin
Ativan
Aventyl
Buspar
Celexa
Clozaril
Concerta
Cylert
Cymbalta
Dalmane
Depakene
Depakote
Desyrel
Dexedrine
Elavil
Eskalith
Focalin
Gabitril
Geodon
Halcion
Haldol
Intuniv
Keppra
Klonopin
Lamictal
Lexapro
Librium
Lithium
Lithobid
Loxitane
Luvox
Marplan
Mellaril
Moban
Nardil
Navane
Neurontin
Norpramin
Orap
Pamelor
Parnate
Paxil
Pertofrane
Prolixin
Prozac
Remeron
Restoril
Risperdal
Ritalin
Sarafem
Serax
Serentil
Seroquel
Serzone
Sinequan
Stelazine
Strattera
Tegretol
Thorazine
Tofranil
Topamax
Trazodone
Trifluoperazine

Trilafon
Trileptal
Valium
Vivactil
Vyvanse
Wellbutrin
Xanax
Zoloft
Zyban
Zyprexa

STRATTERA is a chemical substance that crosses the blood-brain barrier and acts primarily upon the central nervous system where it affects brain function, resulting in changes in perception, mood, consciousness, cognition, and behavior. Strattera also produces a range of physical side effects, as well as undesirable mental and physical manifestations when being discontinued. Because of these, Strattera can be addictive. For information on how to to safely break the dependency on Strattera or discontinue it under medical supervision, click here. For information on your rights if you or a family member is being urged to take Strattera, click here.

The FDA directed Eli Lilly and Company (Lilly), the manufacturer of Strattera (atomoxetine), to revise the prescribing information to include a boxed warning and additional warning statements that alert health care providers of an increased risk of suicidal thinking in children and adolescents being treated with this medication. FDA also informed Lilly that a Patient Medication Guide (MedGuide) should be provided to patients when Strattera is dispensed. The MedGuide advises patients of the risks associated with and precautions that can be taken when Strattera is dispensed. Further, pediatric patients being treated with Strattera should be closely observed for clinical worsening, as well as agitation, irritability, suicidal thinking or behaviors, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.


The Food and Drug Administration (FDA) is advising health care professionals about a new warning for Strattera, a drug approved for attention deficit hyperactivity disorder (ADHD) in adults and children. The labeling is being updated with a bolded warning about the potential for severe liver injury following two reports (a teenager and an adult) in patients who had been treated with Strattera for several months, both of whom recovered.


STRATTERA SIDE EFFECT: Suicidal thoughts and actions in children and teenagers
Children and teenagers sometimes think about suicide, and many report trying to kill themselves. Results from STRATTERA clinical studies with over 2200 child or teenage ADHD patients suggest that some children and teenagers may have a higher chance of having suicidal thoughts or actions.
The chance for suicidal thoughts and actions may be higher:

STRATTERA SIDE EFFECT: Anxiety

A state of uneasiness and apprehension.

STRATTERA SIDE EFFECT: Agitation

Extreme emotional disturbance.

STRATTERA SIDE EFFECT: Panic attack

The sudden onset of intense anxiety, characterized by feelings of intense fear and apprehension and accompanied by palpitations.

STRATTERA SIDE EFFECT: Irritability

Easily irritated or annoyed.

STRATTERA SIDE EFFECT: Hostility

The state of being hostile; antagonism or enmity.

STRATTERA SIDE EFFECT: Restlessness

Marked by a lack of quiet, repose, or rest.

STRATTERA SIDE EFFECT: Mania

An abnormally elated mental state.

STRATTERA SIDE EFFECT: Depression

Feelings of prolonged sadness.

STRATTERA SIDE EFFECT: Suicidal ideation

Strictly speaking, suicidal ideation means wanting to take one's own life or thinking about suicide.

STRATTERA SIDE EFFECT: Sudden Death An instant unexpected death.


STRATTERA SIDE EFFECT: Stroke

The sudden death of a portion of the brain cells due to a lack of oxygen.


STRATTERA SIDE EFFECT: Heart Attack

Sudden interruption or insufficiency of the supply of blood to the heart.

STRATTERA SIDE EFFECT: Psychosis - Psychotic symptoms (such as hearing voices, believing things that are not true, being suspicious) or new manic symptoms.

STRATTERA SIDE EFFECT: Allergic reaction

Trouble breathing, see swelling or hives.

STRATTERA SIDE EFFECT: Hives

An allergic skin reaction causing localized redness, swelling, and itching.

STRATTERA SIDE EFFECT: Nausea

A feeling of sickness in the stomach characterized by an urge to vomit

STRATTERA SIDE EFFECT: Vomitting

To eject part or all of the contents of the stomach through the mouth, usually in a series of involuntary movements.


STRATTERA SIDE EFFECT: Dizziness

Refers to an impairment in spatial perception and stability.


STRATTERA SIDE EFFECT: Mood swing

Alternation of a person's emotional state between periods of euphoria and depression.

STRATTERA SIDE EFFECT: Constipation

Constipation is a decrease in the frequency of stool.

STRATTERA SIDE EFFECT: Insomnia

Inability to obtain sufficient sleep, esp. when chronic.

STRATTERA SIDE EFFECT: Dysuria

Painful or difficult urination.

STRATTERA SIDE EFFECT: Dysmenorrhea

Painful menstruation.

STRATTERA SIDE EFFECT: Prostatitis

Inflammation of the prostate gland.

STRATTERA SIDE EFFECT: Palpitations

Sensation in which a person is aware of an irregular, hard, or rapid heartbeat.


STRATTERA SIDE EFFECT: Tachycardia

Abnormally rapid heart rate.

STRATTERA SIDE EFFECT: ORTHOSTATIC HYPOTENSION - (or·tho·stat·ic (ôr th -st t k). adj. Relating to or caused by standing upright) Plummeting blood pressure that occurs when standing; dizziness and fainting.


STRATTERA SIDE EFFECT: Syncope

Temporary loss of consciousness.

STRATTERA SIDE EFFECT: Hepatitis

Inflammation of the liver, caused by infectious or toxic agents and characterized by jaundice, fever, liver.

STRATTERA SIDE EFFECT: Jaundice

Yellowish discoloration of the whites of the eyes, skin, and mucous membranes caused by deposition of bile salts in these tissues.

STRATTERA SIDE EFFECT: Weight loss

A reduction in body mass characterized by a loss of adipose tissue (body fat) and skeletal muscle.

STRATTERA SIDE EFFECT: Arthralgias

Pain in a joint.

STRATTERA SIDE EFFECT: Diarrhea

Excessive and frequent evacuation of watery feces, usually indicating gastrointestinal distress or disorder.

STRATTERA SIDE EFFECT: Vomitting

To eject part or all of the contents of the stomach through the mouth, usually in a series of involuntary movements.

STRATTERA SIDE EFFECT: Constipation

Constipation is a decrease in the frequency of stool.

STRATTERA SIDE EFFECT: Dyspepsia

Painful, difficult, or disturbed digestion.


STRATTERA SIDE EFFECT: Sinusitis

Inflammation of the sinuses or a sinus, especially in the nasal region.


STRATTERA SIDE EFFECT: Myalgia

Muscular pain.


STRATTERA SIDE EFFECT: Headache

A pain located in the head, as over the eyes, at the temples, or at the base of the skull.

STRATTERA SIDE EFFECT: Paraesthesia

Morbid or perverted sensation; an abnormal sensation, as burning, prickling.


STRATTERA SIDE EFFECT: Somnolence

Drowsiness or sleepiness.

STRATTERA SIDE EFFECT: Tremor

A trembling or shaking usually from physical weakness.

STRATTERA SIDE EFFECT: Seizures

A sudden attack, spasm, or convulsion.

STRATTERA SIDE EFFECT: Hypoesthesia

Abnormally decreased sensitivity, particularly to touch.


STRATTERA SIDE EFFECT: Angioneurotic edema

Acute, localized accumulations of tissue fluid causing swellings around the face.


STRATTERA SIDE EFFECT: Urticaria

Redness and swelling of the skin.


STRATTERA SIDE EFFECT: Urticaria

Redness and swelling of the skin.

STRATTERA SIDE EFFECT: Mydriasis

Prolonged abnormal dilatation of the pupil of the eye caused by disease or a drug.


STRATTERA SIDE EFFECT: Pyrexia - fever

A rise in the temperature of the body; frequently a symptom of infection.


STRATTERA SIDE EFFECT: Rigors

Rigor is a shaking occurring during a high fever.

STRATTERA CLINICAL TRIALS

Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women.
Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE.
Menopause. 2011 Feb 2. [Epub ahead of print], Strattera: 21293309 [Strattera - as supplied by publisher], Related citations

Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.
Benkert D, Krause KH, Wasem J, Aidelsburger P., GMS Health Technol Assess. 2010 Sep 7;6:Doc13., Strattera: 21289886 [Strattera - in process]

How Oppositionality, Inattention, and Hyperactivity Affect Response to Atomoxetine Versus Methylphenidate: A Meta-Analysis.
van Wyk GW, Hazell PL, Kohn MR, Granger RR, Walton RJ., J Atten Disord. 2011 Feb 2. [Epub ahead of print], Strattera: 21289234 [Strattera - as supplied by publisher], Related citations

A Comparison of Atomoxetine Administered as Once Versus Twice Daily Dosing on the School and Home Functioning of Children with Attention-Deficit/Hyperactivity Disorder.
Waxmonsky JG, Waschbusch DA, Akinnusi O, Pelham WE., J Child Adolesc Psychopharmacol. 2011 Feb 2. [Epub ahead of print], Strattera: 21288121 [Strattera - as supplied by publisher], Related citations

An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y.
Psychiatry Clin Neurosci. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x., Strattera: 21265936 [Strattera - as supplied by publisher]
Related citations

Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
van den Ban E, Souverein PC, Swaab H, van Engeland H, Egberts TC, Heerdink ER., Atten Defic Hyperact Disord. 2010 Dec;2(4):213-220. Epub 2010 Nov 30., Strattera: 21258431 [Strattera]Free PMC ArticleFree text, Related citations

Deepened extinction following compound stimulus presentation: noradrenergic modulation.
Janak PH, Corbit LH., Learn Mem. 2010 Dec 14;18(1):1-10. doi: 10.1101/lm.1923211. Print 2011., Strattera: 21224211 [Strattera - in process]
Related citations

Atomoxetine-induced myocardial infarction.
Seifi A, Griffith H, Avestimehr S, Dib H., South Med J. 2011 Feb;104(2):153-4.
Strattera: 21206410 [Strattera - in process], Related citations

Pragmatic measures in paediatric psychopharmacology - Are we getting it right?
Coghill D., Eur Neuropsychopharmacol. 2010 Dec 29. [Epub ahead of print]
Strattera: 21194897 [Strattera - as supplied by publisher], Related citations

Methylphenidate But Not Atomoxetine or Citalopram Modulates Inhibitory Control and Response Time Variability.
Nandam LS, Hester R, Wagner J, Cummins TD, Garner K, Dean AJ, Kim BN, Nathan PJ, Mattingley JB, Bellgrove MA., Biol Psychiatry. 2010 Dec 28. [Epub ahead of print], Strattera: 21193172 [Strattera - as supplied by publisher]
Related citations

Pharmacotherapeutics of tourette syndrome and stereotypies in autism.
Rajapakse T, Pringsheim T., Semin Pediatr Neurol. 2010 Dec;17(4):254-60.
Strattera: 21183132 [Strattera - in process], Related citations

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Wigal SB, Chae S, Patel A, Steinberg-Epstein R., Semin Pediatr Neurol. 2010 Dec;17(4):230-6., Strattera: 21183129 [Strattera - in process], Related citations

The neurobiological basis of ADHD.
Curatolo P, D'Agati E, Moavero R., Ital J Pediatr. 2010 Dec 22;36(1):79.
Strattera: 21176172 [Strattera - in process]Free PMC ArticleFree text
Related citations

Neural Correlates of Error Monitoring Modulated by Atomoxetine in Healthy Volunteers.
Graf H, Abler B, Freudenmann R, Beschoner P, Schaeffeler E, Spitzer M, Schwab M, Grön G., Biol Psychiatry. 2010 Dec 16. [Epub ahead of print]
Strattera: 21168122 [Strattera - as supplied by publisher], Related citations

Atomoxetine and Methylphenidate Treatment in Children with ADHD: The Efficacy, Tolerability and Effects on Executive Functions.
Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B., Child Psychiatry Hum Dev. 2010 Dec 17. [Epub ahead of print], Strattera: 21165694 [Strattera - as supplied by publisher], Related citations

Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
Wilens TE, Gault LM, Childress A, Kratochvil CJ, Bensman L, Hall CM, Olson E, Robieson WZ, Garimella TS, Abi-Saab WM, Apostol G, Saltarelli MD.
J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):73-84.e1. Epub 2010 Nov 25., Strattera: 21156272 [Strattera - in process], Related citations

The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects.
Dell'osso B, Palazzo MC, Oldani L, Altamura AC., CNS Neurosci Ther. 2010 Dec 14. doi: 10.1111/j.1755-5949.2010.00217.x. [Epub ahead of print]
Strattera: 21155988 [Strattera - as supplied by publisher], Related citations

Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy.
Torres A, Whitney J, Rao S, Tilley C, Lobel R, Gonzalez-Heydrich J., Epilepsy Behav. 2011 Jan;20(1):95-102. Epub 2010 Dec 13., Strattera: 21146461 [Strattera - in process], Related citations

Prevalence in adults of attention deficit hyperactivity disorder using the medical records of primary care.
Aragonès E, Lluís Piñol J, Ramos-Quiroga JA, López-Cortacans G, Caballero A, Bosch R., Rev Esp Salud Publica. 2010 Jul-Aug;84(4):417-22. Spanish.
Strattera: 21141268 [Strattera - indexed for MEDLINE], Related citations

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.
Wehmeier PM, Schacht A, Dittmann RW, Helsberg K, Schneider-Fresenius C, Lehmann M, Bullinger M, Ravens-Sieberer U., Qual Life Res. 2010 Dec 7. [Epub ahead of print], Strattera: 21136299 [Strattera - as supplied by publisher], Related citations

Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials.
Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V., Child Adolesc Psychiatry Ment Health. 2010 Dec 6;4:30., Strattera: 21134277 [Strattera - in process]Free PMC ArticleFree text, Related citations

Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure.
Bizot JC, David S, Trovero F., Neurosci Lett. 2011 Feb 1;489(1):20-4. Epub 2010 Dec 1., Strattera: 21129437 [Strattera - in process], Related citations

Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder.
Ramos-Quiroga JA, Casas M., CNS Drugs. 2011 Jan 1;25(1):17-36. doi: 10.2165/11538450-000000000-00000., Strattera: 21128692 [Strattera - in process], Related citations

Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Report Update 3 [Internet].
McDonagh MS, Christensen V, Peterson K, Thakurta S., Portland (OR): Oregon Health & Science University; 2009 Oct., Strattera: 21089242 [Strattera]Books & DocumentsFree text, Related citations

Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
Hazell P., Australas Psychiatry. 2010 Dec;18(6):556-9., Strattera: 21117844 [Strattera - in process], Related citations

Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking.
Economidou D, Dalley JW, Everitt BJ., Biol Psychiatry. 2011 Feb 1;69(3):266-74. Epub 2010 Dec 15., Strattera: 21109233 [Strattera - in process], Related citations

Translational Approaches to Frontostriatal Dysfunction in Attention-Deficit/Hyperactivity Disorder Using a Computerized Neuropsychological Battery.
Chamberlain SR, Robbins TW, Winder-Rhodes S, Müller U, Sahakian BJ, Blackwell AD, Barnett JH., Biol Psychiatry. 2010 Nov 2. [Epub ahead of print]
Strattera: 21047621 [Strattera - as supplied by publisher], Related citations

A New In Situ Brain Perfusion Flow Correction Method for Lipophilic Drugs Based on the pH-Dependent Crone-Renkin Equation.
Avdeef A, Sun N., Pharm Res. 2010 Nov 2. [Epub ahead of print], Strattera: 21042838 [Strattera - as supplied by publisher], Related citations

Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.
Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC., Br J Clin Pharmacol. 2010 Nov;70(5):721-8. doi: 10.1111/j.1365-2125.2010.03754.x., Strattera: 21039766 [Strattera - in process], Related citations

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.
McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT.
Am J Addict. 2010 Nov;19(6):481-9. doi: 10.1111/j.1521-0391.2010.00076.x. Epub 2010 Sep 21., Strattera: 20958842 [Strattera - in process], Related citations

Efficacy of strattera in children and adolescents with attention deficit hyperactivity disorder.
Vakula IN, Vasyanina YSh, Gorbunova ZKh, Nikiforova EY, Ponomarenko EI.
Neurosci Behav Physiol. 2010 Nov;40(9):1034-7., Strattera: 20953992 [Strattera - in process], Related citations

Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.
Paterson NE, Ricciardi J, Wetzler C, Hanania T., Neurosci Res. 2011 Jan;69(1):41-50. Epub 2010 Oct 8., Strattera: 20934466 [Strattera - in process], Related citations

Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Fernández-Jaén A, Fernández-Mayoralas DM, Calleja Pérez B, Muñoz Jareño N, Campos Díaz Mdel R., Pediatr Neurol. 2010 Nov;43(5):341-7., Strattera: 20933178 [Strattera - in process], Related citations

Development and validation of a stability-indicating RP-HPLC method for determination of atomoxetine hydrochloride in tablets.
Patel SK, Patel NJ., J AOAC Int. 2010 Jul-Aug;93(4):1207-14., Strattera: 20922953 [Strattera - indexed for MEDLINE], Related citations

Changes in Emotions Related to Medication Used to Treat ADHD. Part I: A Literature Review.
Manos MJ, Brams M, Childress AC, Findling RL, Lopez FA, Jensen PS.
J Atten Disord. 2010 Sep 28. [Epub ahead of print], Strattera: 20876887 [Strattera - as supplied by publisher], Related citations

Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.
Gallezot JD, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, Maguire RP, Carson RE, Ding YS., Neuroimage. 2010 Sep 29. [Epub ahead of print]
Strattera: 20869448 [Strattera - as supplied by publisher], Related citations

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Sasané R, Hodgkins P, Meijer W., Curr Med Res Opin. 2010 Nov;26(11):2565-74. Epub 2010 Sep 23., Strattera: 20863165 [Strattera - in process], Related citations

Understanding attention-deficit/hyperactivity disorder from childhood to adulthood.
Wilens TE, Spencer TJ., Postgrad Med. 2010 Sep;122(5):97-109. Review.
Strattera: 20861593 [Strattera - indexed for MEDLINE], Related citations

Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
Sumner CR, Haynes VS, Teicher MH, Newcorn JH., Postgrad Med. 2010 Sep;122(5):52-61., Strattera: 20861588 [Strattera - indexed for MEDLINE]
Related citations

Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.
Gamo NJ, Wang M, Arnsten AF., J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1011-23. Epub 2010 Sep 1., Strattera: 20855046 [Strattera - indexed for MEDLINE]Free PMC ArticleFree text, Related citations

The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review.
Coghill D., CNS Drugs. 2010 Oct 1;24(10):843-66. doi: 10.2165/11537450-000000000-00000. Review., Strattera: 20839896 [Strattera - indexed for MEDLINE], Related citations

Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis.
Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, van Wyk GW.
J Atten Disord. 2010 Sep 28. [Epub ahead of print], Strattera: 20837981 [Strattera - as supplied by publisher], Related citations

Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
Sallee FR, Eaton K., Expert Opin Pharmacother. 2010 Oct;11(15):2549-56.
Strattera: 20831361 [Strattera - in process], Related citations

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Stiefel G, Besag FM., Drug Saf. 2010 Oct 1;33(10):821-42. doi:, 10.2165/11536380-000000000-00000. Review., Strattera: 20812768 [Strattera - indexed for MEDLINE], Related citations

Use of psychostimulants in patients with dementia.
Dolder CR, Davis LN, McKinsey J., Ann Pharmacother. 2010 Oct;44(10):1624-32. Epub 2010 Aug 24. Review., Strattera: 20736422 [Strattera - indexed for MEDLINE], Related citations

Attention-deficit/Hyperactivity Disorder in the context of Autism spectrum disorders.
Murray MJ., Curr Psychiatry Rep. 2010 Oct;12(5):382-8. Review., Strattera: 20694583 [Strattera - indexed for MEDLINE], Related citations

Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
ter Laak MA, Temmink AH, Koeken A, van 't Veer NE, van Hattum PR, Cobbaert CM., Pediatr Neurol. 2010 Sep;43(3):159-62., Strattera: 20691935 [Strattera - indexed for MEDLINE], Related citations

Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
Fumagalli F, Cattaneo A, Caffino L, Ibba M, Racagni G, Carboni E, Gennarelli M, Riva MA., Pharmacol Res. 2010 Dec;62(6):523-9. Epub 2010 Aug 5.
Strattera: 20691787 [Strattera - in process], Related citations

Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD: An Open-Label Study.
Charnsil C., J Atten Disord. 2010 Aug 4. [Epub ahead of print], Strattera: 20686100 [Strattera - as supplied by publisher], Related citations

Electrochemical behavior of atomoxetine and its voltammetric determination in capsules.
Pérez-Ortiz M, Muñoz C, Zapata-Urzúa C, Alvarez-Lueje A., Talanta. 2010 Jun 30;82(1):398-403. Epub 2010 May 7., Strattera: 20685484 [Strattera - indexed for MEDLINE], Related citations

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB., Neurology. 2010 Aug 3;75(5):448-55., Strattera: 20679638 [Strattera - indexed for MEDLINE]
Related citations

Treatment of preschoolers with attention-deficit/hyperactivity disorder.
Murray DW., Curr Psychiatry Rep. 2010 Oct;12(5):374-81. Review., Strattera: 20676944 [Strattera - indexed for MEDLINE], Related citations

The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.
Montezinho LP, Miller S, Plath N, Jensen NH, Karlsson JJ, Witten L, Mørk A.
Psychopharmacology (Berl). 2010 Oct;212(2):131-43. Epub 2010 Jul 30.
Strattera: 20676614 [Strattera - indexed for MEDLINE], Related citations

Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Waxmonsky JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L., J Clin Psychiatry. 2010 Nov;71(11):1535-51. Epub 2010 Jun 29.
Strattera: 20673557 [Strattera - indexed for MEDLINE], Related citations

Once-daily atomoxetine in the treatment of attention-deficit/hyperactivity disorder in adults.
Lall AS, Averbuch R., Curr Psychiatry Rep. 2010 Oct;12(5):363-5. No abstract available., Strattera: 20665133 [Strattera], Related citations

Gateways to clinical trials.
Tomillero A, Moral MA., Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88., Strattera: 20664824 [Strattera - indexed for MEDLINE], Related citations

Treatment of chronic akinetic mutism with atomoxetine: subtraction analysis of brain f-18 fluorodeoxyglucose positron emission tomographic images before and after medication: a case report.
Kim YW, Shin JC, An YS., Clin Neuropharmacol. 2010 Jul;33(4):209-11.
Strattera: 20661027 [Strattera - indexed for MEDLINE], Related citations

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
Saylor K, Williams DW, Schuh KJ, Wietecha L, Greenbaum M., Curr Med Res Opin. 2010 Sep;26(9):2087-95., Strattera: 20642391 [Strattera - indexed for MEDLINE], Related citations

Enhancing the salience of dullness: behavioral and pharmacological strategies to facilitate extinction of drug-cue associations in adolescent rats.
Brenhouse HC, Dumais K, Andersen SL., Neuroscience. 2010 Aug, 25;169(2):628-36., Strattera: 20639130 [Strattera - indexed for MEDLINE]
Related citations

How adolescents with substance use disorder spend research payments.
Thurstone C, Salomensen-Sautel S, Riggs PD., Drug Alcohol Depend. 2010 Oct 1;111(3):262-4. Epub 2010 Jun 3., Strattera: 20627618 [Strattera - in process], Related citations

Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Roman MW., Issues Ment Health Nurs. 2010 Aug;31(8):548-9. No abstract available., Strattera: 20624025 [Strattera - indexed for MEDLINE], Related citations

Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky MJ, Strom BL., Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):934-41.
Strattera: 20623519 [Strattera - indexed for MEDLINE], Related citations

Aripiprazole for the tic symptoms in a child receiving atomoxetine treatment for ADHD.
Yu SH, Chou JY, Robson D, Chen VC., Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1355-6. Epub 2010 Jul 7. No abstract available.
Strattera: 20619310 [Strattera - indexed for MEDLINE], Related citations

Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Scott NG, Ripperger-Suhler J, Rajab MH, Kjar D., J Child Adolesc Psychopharmacol. 2010 Jun;20(3):197-203., Strattera: 20578932 [Strattera - indexed for MEDLINE], Related citations

Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
Montoya A, Escobar R, García-Polavieja MJ, Lachno DR, Alda JÁ, Artigas J, Cardo E, García M, Gastaminza X, Gilaberte I., J Child Neurol. 2011 Jan;26(1):31-6. Epub 2010 Jun 4., Strattera: 20525942 [Strattera - in process]
Related citations

Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients.
Block SL, Williams D, Donnelly CL, Dunn DW, Saylor KE, Ruberg SJ., Clin Pediatr (Phila). 2010 Aug;49(8):768-76. Epub 2010 Jun 3., Strattera: 20522617 [Strattera - indexed for MEDLINE], Related citations

Attention deficit hyperactivity disorder in adults.
Rösler M, Casas M, Konofal E, Buitelaar J., World J Biol Psychiatry. 2010 Aug;11(5):684-98. Review., Strattera: 20521876 [Strattera - indexed for MEDLINE], Related citations

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM., Clin Pharmacol Ther. 2010 Jul;88(1):69-78. Epub 2010 Jun 2., Strattera: 20520602 [Strattera - indexed for MEDLINE], Related citations

Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials.
Escobar R, Schacht A, Wehmeier PM, Wagner T., J Clin Psychopharmacol. 2010 Apr;30(2):145-51., Strattera: 20520287 [Strattera - in process]
Related citations

Pharmacogenetic approach for a better drug treatment in children.
Polanczyk G, Bigarella MP, Hutz MH, Rohde LA., Curr Pharm Des. 2010;16(22):2462-73. Review., Strattera: 20513229 [Strattera - indexed for MEDLINE], Related citations

Gateways to clinical trials.
Tomillero A, Moral MA., Methods Find Exp Clin Pharmacol. 2010, May;32(4):247-88., Strattera: 20508873 [Strattera - indexed for MEDLINE]
Related citations

Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.
Cascade E, Kalali AH, Wigal SB., Psychiatry (Edgmont). 2010 Apr;7(4):13-5.
Strattera: 20508803 [Strattera - in process]Free PMC ArticleFree text, Related citations

Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.
Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK.
J Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):573-82., Strattera: 20494267 [Strattera - indexed for MEDLINE], Related citations

Impact of psychostimulants and atomoxetine on the expression of 8-hydroxyguanine glycosylase 1 in human cells.
Schmidt AJ, Clement HW, Gebhardt S, Hemmeter UM, Schulz E, Krieg JC, Kircher T, Heiser P., J Neural Transm. 2010 Jun;117(6):793-7. Epub 2010 May 14., Strattera: 20467764 [Strattera - indexed for MEDLINE], Related citations

Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
[No authors listed], Prescrire Int. 2010 Feb;19(105):5-8., Strattera: 20455329 [Strattera - indexed for MEDLINE], Related citations

Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations.
Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Föhr KJ., Br J Pharmacol. 2010 May;160(2):283-91., Strattera: 20423340 [Strattera - indexed for MEDLINE], Related citations

Combining atomoxetine with carbamazepine or neuroleptics reduces adverse side effects.
Niederhofer H., J Paediatr Child Health. 2010 Jan;46(1-2):66. No abstract available., Strattera: 20412195 [Strattera - indexed for MEDLINE], Related citations

Effects of atomoxetine on levels of monoamines and related substances in discrete brain regions in mice intermittently deprived of rapid eye movement sleep.
Niijima F, Saito H, Murai S, Arai Y, Nakagawasai O, Tan-No K, Watanabe H, Hiraga H, Tadano T., Biol Pharm Bull. 2010;33(4):617-21., Strattera: 20410595 [Strattera - indexed for MEDLINE]Free Article, Related citations

Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice.
Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T., J Neurochem. 2010 Jul;114(1):259-70. Epub 2010 Apr 16., Strattera: 20403082 [Strattera - indexed for MEDLINE], Related citations

Gateways to clinical trials.
Tomillero A, Moral MA., Methods Find Exp Clin Pharmacol. 2010 Mar;32(2):133-47., Strattera: 20401351 [Strattera - indexed for MEDLINE]
Related citations

Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.
Kobayashi T, Washiyama K, Ikeda K., Neuropsychopharmacology. 2010 Jun;35(7):1560-9. Epub 2010 Mar 10., Strattera: 20393461 [Strattera - indexed for MEDLINE], Related citations

The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.
Lang HC, Scheffler RM, Hu TW., Health Policy. 2010 Sep;97(1):71-8. Epub 2010 Apr 10., Strattera: 20382439 [Strattera - indexed for MEDLINE]
Related citations

EEG-vigilance and response to stimulants in paediatric patients with attention deficit/hyperactivity disorder.
Sander C, Arns M, Olbrich S, Hegerl U., Clin Neurophysiol. 2010, Sep;121(9):1511-8. Epub 2010 Apr 9., Strattera: 20382071 [Strattera - indexed for MEDLINE], Related citations

Pharmacologic mood destabilization: case vignettes.
Swann AC., CNS Spectr. 2009 Nov;14(11 Suppl 11):9-11; discussion 12-4. Review. No abstract available., Strattera: 20173695 [Strattera - indexed for MEDLINE], Related citations

A current update on ADHD pharmacogenomics.
Kieling C, Genro JP, Hutz MH, Rohde LA., Pharmacogenomics. 2010 Mar;11(3):407-19. Review., Strattera: 20235795 [Strattera - indexed for MEDLINE], Related citations

Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.
Dittmann RW, Wehmeier PM, Schacht A, Lehmann M, Lehmkuhl G.
Atten Defic Hyperact Disord. 2009 Dec;1(2):187-200. Epub 2009 Sep 23.
Strattera: 20234829 [Strattera]Free PMC ArticleFree text
Related citations

Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Ponsler G, Dittmann RW., Atten Defic Hyperact Disord. 2009 Dec;1(2):201-210. Epub 2009 Sep 23., Strattera: 20234828 [Strattera]Free PMC ArticleFree text, Related citations

Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD.
Gerhard T, Winterstein AG, Olfson M, Huang C, Saidi A, Crystal S., Pharmacoepidemiol Drug Saf. 2010 May;19(5):457-64., Strattera: 20232490 [Strattera - indexed for MEDLINE], Related citations

A pilot study to evaluate a community pharmacy-based monitoring system to identify adverse drug reactions associated with paediatric medicines use.
Tobaiqy M, Stewart D, Helms PJ, Bond C, Lee AJ, Bateman N, McCaig D, McLay J., Eur J Clin Pharmacol. 2010 Jun;66(6):627-32. Epub 2010 Mar 2.
Strattera: 20195588 [Strattera - indexed for MEDLINE], Related citations

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S., Curr Med Res Opin. 2010 Apr;26(4):977-89., Strattera: 20178404 [Strattera - indexed for MEDLINE]
Related citations

Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T., J Child Adolesc Psychopharmacol. 2010 Feb;20(1):55-61., Strattera: 20166797 [Strattera - indexed for MEDLINE], Related citations

Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.
Ruocco LA, Carnevale UA, Treno C, Sadile AG, Melisi D, Arra C, Ibba M, Schirru C, Carboni E., Behav Brain Res. 2010 Jun 26;210(1):99-106. Epub 2010 Feb 13., Strattera: 20156489 [Strattera - indexed for MEDLINE]
Related citations

Principles of medical care for children with attention deficit hyperactivity disorder.
Chutko LS, Yur'eva RG, Surushkina SY, Nikishena IS, Yakovenko IS, Anisimova TI, Aitbekov KA., Neurosci Behav Physiol. 2010 Mar;40(3):351-5. Review. No abstract available., Strattera: 20151327 [Strattera - indexed for MEDLINE]
Related citations

Gateways to clinical trials.
Tomillero A, Moral MA., Methods Find Exp Clin Pharmacol. 2009, Nov;31(9):597-633., Strattera: 20094643 [Strattera - indexed for MEDLINE]
Related citations

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.
Froehlich TE, McGough JJ, Stein MA., CNS Drugs. 2010 Feb 1;24(2):99-117. doi: 10.2165/11530290-000000000-00000. Review., Strattera: 20088618 [Strattera - indexed for MEDLINE]Free PMC ArticleFree text, Related citations

Cognitive enhancement as a pharmacotherapy target for stimulant addiction.
Sofuoglu M., Addiction. 2010 Jan;105(1):38-48. Review., Strattera: 20078461 [Strattera - indexed for MEDLINE]Free PMC ArticleFree text, Related citations

Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.
Surman C, Hammerness P, Petty C, Doyle R, Chu N, Gebhard N, Williams C, Biederman J., CNS Neurosci Ther. 2010 Spring;16(1):6-12., Strattera: 20070786 [Strattera - indexed for MEDLINE], Related citations

Occurrence and treatment of ADHD in adults.
Meyer JS., CNS Neurosci Ther. 2010 Spring;16(1):1-2. No abstract available.
Strattera: 20070784 [Strattera - indexed for MEDLINE], Related citations

Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge.
O'Sullivan JB, Ryan KM, Harkin A, Connor TJ., J Neuroimmunol. 2010 Mar 30;220(1-2):34-42. Epub 2010 Jan 12., Strattera: 20061033 [Strattera - indexed for MEDLINE], Related citations

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV, Glatt SJ., J Clin Psychiatry. 2010 Jun;71(6):754-63. Epub 2009 Dec 29., Strattera: 20051220 [Strattera - indexed for MEDLINE], Related citations

 

ad1

ad2

ADVERTISEMENTad3

gray_line

Custom Search


LINKS


TERMS OF USE—LEGAL DISCLAIMER:

1.This website is intended only to provide information in general. Listed side effects, references to medical publications or other statements found herein are only
for informational purposes and do not constitute medical advice. Only a licensed health care professional should diagnose a health or medical problem and
prescribe treatment.

2. DO NOT DISCONTINUE OR CHANGE MEDICATION BASED ON INFORMATION AT THIS WEBSITE. Consult your physician if you are experiencing side effects
or want to discontinue taking a drug.


Copyright © 2010 AboutPsychDrugs.com. All rights reserved. Use of this website constitutes acceptance of the Terms of Use.